ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.686,60
1,07%
S&P 500
5.211,71
0,46%
Dow Jones
39.371,98
0,81%
Euro vs US Dollar
1,07805
0,32%
Bitcoin
62.201,76
1,66%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Akari Therapeutics PLC (AKTX)

  7. Akari Therapeutics PLC (AKTX) News

AKTX

Akari Therapeutics (AKTX)

Akari Therapeutics PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AKTX
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
15/03/202417h53PR Newswire (US)Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law FirmNASDAQ:AKTXAkari Therapeutics PLC
11/03/202422h25Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
11/03/202422h24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
05/03/202422h57Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
05/03/202414h34Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
05/03/202414h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
09/01/202423h25Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
04/01/202418h34Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
03/01/202402h06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
03/01/202401h56Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
03/01/202401h49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
03/01/202400h58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
03/01/202400h41Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
02/01/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
01/12/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
16/11/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202322h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AKTXAkari Therapeutics PLC
27/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
24/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
24/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
20/10/202323h00Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
20/10/202322h29Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKTXAkari Therapeutics PLC
20/10/202322h28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKTXAkari Therapeutics PLC
20/10/202322h23Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:AKTXAkari Therapeutics PLC
19/10/202322h17Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
12/10/202322h43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKTXAkari Therapeutics PLC
29/09/202314h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
21/09/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
05/09/202315h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AKTX

Kürzlich von Ihnen besucht

CCOM
SILVER
SILVER
TG
RHM
Rheinmetall
TG
BAYN
Bayer
TG
DTE
Deutsche Telekom
DBI
MDAX
MDAX
FX
EURUSD
Euro vs US Dollar
TG
CBK
Commerzbank
CCOM
US500
US 500
AMEX
XLV
Health Care Select Sector
NYSE
MRK
Merck
TG
ALV
Allianz
NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
TG
MBG
MercedesBenz
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten